Holen Sie sich die Stockscreener-App
2.63
1.54%
0.04
Vorhandelsmarkt:
2.63
Schlusskurs vom Vortag:
$2.59
Offen:
$2.56
24-Stunden-Volumen:
84,266
Relative Volume:
0.24
Marktkapitalisierung:
$2.01M
Einnahmen:
$202.00K
Nettoeinkommen (Verlust:
$-28.96M
KGV:
-4.3833
EPS:
-0.6
Netto-Cashflow:
$-21.85M
1W Leistung:
-9.93%
1M Leistung:
-71.07%
6M Leistung:
+1,665%
1J Leistung:
+888.72%
1-Tages-Spanne:
$2.52
$2.7111
1-Wochen-Bereich:
$2.46
$2.96
52-Wochen-Spanne:
$0.0633
$20.35
AIM ImmunoTech Inc Stock (AIM) Company Profile
Firmenname
AIM ImmunoTech Inc
Sektor
Branche
Telefon
352 448 7797
Adresse
2117 SW Highway 484, Ocala, FL
Vergleichen Sie AIM mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
AIM
AIM ImmunoTech Inc
|
2.63 | 7.16M | 202.00K | -28.96M | -21.85M | -0.60 |
|
VRTX
Vertex Pharmaceuticals Inc
|
387.77 | 96.01B | 11.42B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
556.55 | 57.86B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
429.93 | 57.02B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
637.56 | 39.10B | 3.05B | 1.28B | -614.78M | 19.58 |
|
ONC
Beone Medicines Ltd Adr
|
288.10 | 34.45B | 3.81B | -644.79M | -669.77M | -6.24 |
AIM ImmunoTech Inc Aktie (AIM) Neueste Nachrichten
AIM ImmunoTech Announces Pricing of $8.0 Million Public Offering - 富途牛牛
AIM ImmunoTech’s Oncology Drug Ampligen to Be Featured in - GlobeNewswire
AIM ImmunoTech's Oncology Drug Ampligen to Be Featured in Key Pr - GuruFocus
Breakthrough: New Cancer Drug Ampligen Delivers Promising Results in Pancreatic, Ovarian, and Breast Cancer Trials - Stock Titan
AIM ImmunoTech (AIM) Advances Clinical Trials and Strengthens Financial Position - GuruFocus
AIM ImmunoTech Builds Positive Momentum and Reiterates Focus on - GuruFocus
AIM ImmunoTech Builds Positive Momentum and Reiterates Focus on Driving Ampligen® Clinical Development Toward Pancreatic Cancer Approval | AIM Stock News - GuruFocus
AIM ImmunoTech Builds Positive Momentum and Reiterates - GlobeNewswire
Breakthrough in Pancreatic Cancer Treatment: AIM's Ampligen-Imfinzi Combo Shows Positive Survival Data - Stock Titan
AIM ImmunoTech Surges Amid Key Developments, Raises $8 Million in Public Offering - AInvest
AIM ImmunoTech Closes $8 Million Public Offering - MSN
Latest News - Asia Food Journal
AIM ImmunoTech Announces Closing of $8.0 Million Public Offering - GlobeNewswire
AIM ImmunoTech's $8.0M Capital Raise: A Strategic Move to Fuel Ampligen's Clinical Progress and Investor Value? - AInvest
AIM ImmunoTech closes public offering, raises $8 mln. - AInvest
AIM ImmunoTech Secures $8M Funding: New Shares at $4.00 Plus 5-Year Warrants - Stock Titan
AIM ImmunoTech reports Ampligen combo trial data for pancreatic cancer - MSN
Biotech Alert: Searches spiking for these stocks today - TipRanks
AIM ImmunoTech's Stock Falls 50% Following $8M Securities Offering - AInvest
Evaluating AIM ImmunoTech's Capital Raise: A Strategic Crossroads for Investors - AInvest
AIM Shares Fall After Pricing of $8 Million Public Offering - MarketScreener
Crude Oil Gains Over 1%; UnitedHealth Earnings Miss Views - Benzinga
AIM ImmunoTech stock plunges after pricing $8 million public offering By Investing.com - Investing.com Australia
AIM ImmunoTech stock plunges after pricing $8 million public offering - Investing.com
US Stocks Mixed; Procter & Gamble Posts Upbeat Earnings - Benzinga
AIM ImmunoTech Stock Dives 50% After Priced Public Offering - AInvest
Why Is AIM ImmunoTech Stock (AIM) Down 50% Today? - TipRanks
AIM ImmunoTech prices $8 million public offering at $4.00 per share - Investing.com
AIM ImmunoTech Plunges 51.11% Amid Market Volatility - AInvest
AIM ImmunoTech prices 2M shares at $4.00 in public offering - TipRanks
AIM ImmunoTech Announces $8 Million Public Offering at $4 per Share with Accompanying Warrants. - AInvest
AIM ImmunoTech Secures Fresh Capital: $8M Offering Includes Dual Warrant Structure at $4.00 - Stock Titan
AIM ImmunoTech Inc Plunges 38.33% Amid Trading Halt - AInvest
AIM ImmunoTech Stock Plunges 40.97% on Volatility - AInvest
Why Celestica Shares Are Trading Higher By Around 12%; Here Are 20 Stocks Moving Premarket - Benzinga
AIM ImmunoTech Plunges 27.08% Amid Volatility Concerns - AInvest
AIM ImmunoTech Reports Positive Mid-year Safety and - GlobeNewswire
AIM ImmunoTech Inc. Trading Resumes: Enhanced Tools and Expert Analysis Available for Investors - AInvest
Crude Oil Gains 2%; CEA Industries Shares Spike Higher - Benzinga
Why Is Micro-Cap AIM ImmunoTech Stock Surging? - Benzinga
AIM ImmunoTech's Ampligen: A Promising Catalyst for Shareholder Value in Pancreatic Cancer Therapy - AInvest
US Stocks Mixed; Enterprise Products Partners Posts Upbeat Earnings - Benzinga
AIM ImmunoTech Reports Positive Phase 2 Study Results - TipRanks
AIM ImmunoTech (AIM) reveals positive Phase 2 Ampligen pancreatic data | AIM SEC FilingForm 8-K - Stock Titan
AIM ImmunoTech Reports Positive Mid-year Safety and Efficacy Data from Phase 2 Study Evaluating Ampligen® (rintatolimod) in Combination with AstraZeneca’s Imfinzi® (durvalumab) for the Treatment of Pancreatic Cancer - GlobeNewswire
Breakthrough in Pancreatic Cancer Treatment: New Phase 2 Data Shows 64% Survival Rate at 6 Months - Stock Titan
AIM ImmunoTech (NYSE:AIM) Stock Price Down 4.5% – Here’s What Happened - Defense World
AIM ImmunoTech granted U.S. patent for Ampligen - MSN
Omega Therapeutics (NASDAQ:OMGA) versus AIM ImmunoTech (NYSE:AIM) Head-To-Head Review - Defense World
AIM ImmunoTech Reveals Major European Expansion Plan for Cancer Drug Development - Stock Titan
AIM ImmunoTech (NYSE:AIM) Shares Gap Up – Here’s What Happened - Defense World
Finanzdaten der AIM ImmunoTech Inc-Aktie (AIM)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.91%
3.06%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):